Prelude Therapeutics Files 8-K on Shareholder Vote Matters
Ticker: PRLD · Form: 8-K · Filed: Jun 18, 2024 · CIK: 1678660
Sentiment: neutral
Topics: shareholder-vote, corporate-governance, sec-filing
TL;DR
Prelude Therapeutics is asking shareholders to vote on important company matters.
AI Summary
On June 14, 2024, Prelude Therapeutics Incorporated filed an 8-K report detailing the submission of matters to a vote of its security holders. The filing indicates that the company is seeking approval from its shareholders on certain proposals. The report was officially filed with the SEC on June 18, 2024.
Why It Matters
This filing signals that Prelude Therapeutics is engaging its shareholders in key corporate decisions, which could impact the company's future direction and governance.
Risk Assessment
Risk Level: low — The filing is a routine procedural report regarding a shareholder vote, not indicating any immediate financial distress or significant operational change.
Key Players & Entities
- Prelude Therapeutics Incorporated (company) — Registrant
- June 14, 2024 (date) — Earliest event reported
- June 18, 2024 (date) — Filing date
- Delaware (location) — State of incorporation
FAQ
What specific matters are being submitted for a vote of Prelude Therapeutics' security holders?
The filing states that matters are being submitted to a vote of security holders, but does not specify the exact proposals in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on June 14, 2024.
On what date was this 8-K filing officially submitted to the SEC?
The filing was officially submitted to the SEC on June 18, 2024.
What is Prelude Therapeutics Incorporated's state of incorporation?
Prelude Therapeutics Incorporated is incorporated in Delaware.
What is the principal executive office address for Prelude Therapeutics?
The principal executive offices are located at 175 Innovation Boulevard, Wilmington, Delaware, 19805.
Filing Stats: 522 words · 2 min read · ~2 pages · Grade level 10.4 · Accepted 2024-06-18 16:06:18
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share PRLD Nasdaq Glo
Filing Documents
- prld-20240614.htm (8-K) — 53KB
- 0000950170-24-074846.txt ( ) — 189KB
- prld-20240614.xsd (EX-101.SCH) — 44KB
- prld-20240614_htm.xml (XML) — 5KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On June 14, 2024, Prelude Therapeutics Incorporated (the " Company ") held its 2024 Annual Meeting of Stockholders (the " Annual Meeting ") and the following proposals were adopted: 1. Election of two Class I Directors, Paul A. Friedman, M.D., and David P. Bonita, M.D., each to serve a three-year term, which will expire at the 2027 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director's earlier resignation or removal. The vote tally was as follows: Nominees Shares For Shares Withheld Broker Non-Votes Paul A. Friedman, M.D. 31,165,370 1,762,716 2,138,095 David P. Bonita, M.D. 31,007,172 1,920,914 2,138,095 2. Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024. The vote tally was as follows: Shares For Shares Against Shares Abstaining Broker Non-Votes 34,994,229 57,512 14,440 0 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PRELUDE THERAPEUTICS INCORPORATED Date: June 18, 2024 By: / s/ Bryant Lim Bryant Lim Chief Legal Officer, Corporate Secretary, and Interim Chief Financial Officer